ArticleBlood advances2021

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

Jeremy S Abramson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.